2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1738

Assessing the Validity of the Multi-Biomarker Disease Activity Assay in Patients with Psoriatic Arthritis
Abstract Number: 2412

Assessment and Comparison of Responsiveness of Four Patient Reported Outcome Measures to Assess Physical Function in Patients with Knee Osteoarthritis: WOMAC-PF Subscale Responds Best
Abstract Number: 1068

Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE
Abstract Number: 1320

Assessment of 18F-Fluoro-Deoxyglucose Uptake in the Ascending Aorta of Rheumatoid Arthritis Patients
Abstract Number: 1185

Assessment of a Rheumatology Curriculum Utilizing Multiple Learning Modalities
Abstract Number: 2891

Assessment of Disability Levels in a Cohort of 1,489 Patients with Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data from Three Phase III, Randomized, Controlled Trials
Abstract Number: 1333

Assessment of Focal Fat Infiltration in Sacroiliac Joints in Patients with Spondyloarthritis By 1.5T Versus 3.0T Magnetic Resonance Imaging: Is the Field Strength Important to Contrast to Noise Ratios, Reproducibility and Total Scores?
Abstract Number: 12L

Assessment of Immunogenicity of Live Zoster Vaccination (Zostavax®) in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo
Abstract Number: 1464

Assessment of Left Ventricle Functions in Children with Familial Mediterranean Fever with Tissue Doppler and Strain Echocardiography
Abstract Number: 638

Assessment of Myocardial Abnormalities in Primary Sjögren Syndrome Using a Comprehensive Cardiac Magnetic Resonance Approach
Abstract Number: 2990

Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort
Abstract Number: 669

Assessment of Spinal Mobility in Axial Spondyloarthritis: First Validation Steps of a New Electronic Quantification Tool
Abstract Number: 1903

Assessment of Subclinical Atherosclerosis in Patients with Systemic Sclerosis: Results from a Multicentric Cohort
Abstract Number: 2980

Assessment of Sublingual Frenulum Perfusion in Systemic Sclerosis
Abstract Number: 356

Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].